CatchMe Theraputics
Precision Medicine for Epitranscriptome Machinery
Company Overview
Snapshot
Founded in August 2021 by Yael Tsalenchuck, CatchMe Theraputics operates with 1–10 employees. The company has secured funding across one round from FutuRx in December 2021.
Business overview
CatchMe Theraputics is a Health Tech & Life Sciences company focused on developing precision medicine solutions. The company's core technology involves specific inhibition based on the in vivo biological binding preference of targeted proteins, with a versatile platform designed to target various methyl binding proteins and indications. It operates in the Pharma & Medical Biotechnology sector, specifically in Drugs Discovery & Development, serving markets such as hospitals, pharmaceuticals, and cancer therapy globally and in Israel.
Log in to access full profile ›Company Intelligence Q&A
- What is CatchMe Theraputics' primary focus?
- CatchMe Theraputics focuses on precision medicine for epitranscriptome machinery, developing solutions for specific inhibition based on the in vivo biological binding preference of targeted proteins.
- When was CatchMe Theraputics founded?
- CatchMe Theraputics was founded in August 2021.
- Who is a key founder of CatchMe Theraputics?
- Yael Tsalenchuck is a founder and the CSO of CatchMe Theraputics.
- What is the status of CatchMe Theraputics?
- CatchMe Theraputics is non-active and ceased to operate in August 2026.
- Which investor participated in CatchMe Theraputics' funding round?
- In December 2021, FutuRx participated in a Pre-Seed funding round for CatchMe Theraputics.